6-K ·Filed May 27, 2026

ICLR

ICON PLC
BEARISH
Impact 8/10
Horizonweeks Processed4mo ago SEC0001628280-26-038510
Notable filing: 6-K
Actionable Insight ▼ Bearish

The restatement, material weaknesses, and downward revision to backlog methodology create significant uncertainty around ICON's reported financials and future revenue visibility. FY2026 guidance implies further adjusted EPS contraction, and the goodwill impairment signals structural issues in the Data Solutions unit. Monitor the May 28 conference call for details on remediation timeline and whether the Nasdaq deficiency notice (from the delayed 20-F) is resolved. The stock repurchase program provides a floor but does not offset fundamental headwinds.

DirectionBearish
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
ICLR ▲ +25.90% at T+60d
SHORT call ✗ call lost -25.90% · α vs SPY -24.16% · entry $136.80 → $172.23
Entry anchored
May 27, 03:59 PM ET
via exchange tick
T+1d
-0.53%
call +0.53% · α +0.78%
$136.07
settled 4mo ago
T+5d
+5.19%
call -5.19% · α -5.24%
$143.90
settled 4mo ago
T+20d
+24.17%
call -24.17% · α -27.31%
$169.86
settled 3mo ago
T+60d
+25.90%
call -25.90% · α -24.16%
$172.23
settled 6w ago

Price Chart

Loading chart...

Executive Summary

ICON plc filed Q4/FY2025 results alongside the conclusion of an Audit Committee investigation that found revenue overstatements of $65.3M (FY2023) and $92.7M (FY2024), leading to a restatement and disclosure of material weaknesses in internal controls. FY2025 GAAP diluted EPS fell 67.4% YoY to $2.90, adjusted diluted EPS fell 6.3% to $12.53, and adjusted EBITDA declined 8.4% to $1,530.7M; FY2026 guidance calls for revenue of $7,850-$8,150M and adjusted EPS of $10.00-$11.00, implying further contraction. The company also recorded a $364.2M goodwill impairment and a $101M impairment of non-financial assets, and revised its backlog methodology downward by $3.9B.

Key Facts

  • FY2025 GAAP diluted EPS of $2.90 vs $8.90 in FY2024, a decline of 67.4%
  • FY2025 adjusted diluted EPS of $12.53 vs $13.37 in FY2024, a decline of 6.3%
  • FY2025 adjusted EBITDA of $1,530.7M vs $1,670.4M in FY2024, a decline of 8.4%
  • FY2025 revenue of $8,251.3M, up 0.8% YoY (0.1% constant currency)
  • Q4 2025 GAAP diluted EPS of $1.93 vs $3.58 in Q4 2024, a decline of 46.1%
  • Revenue restated downward by $65.3M for FY2023 (0.8%) and $92.7M for FY2024 (1.1%)
  • Material weaknesses in internal control over financial reporting identified
  • Goodwill impairment of $364.2M and impairment of non-financial assets of $101M recorded in FY2025
  • Backlog methodology revised, reducing reported backlog by $3.9B to $21.1B as of Oct 1, 2025
  • FY2026 guidance: revenue $7,850-$8,150M, adjusted diluted EPS $10.00-$11.00
  • $750M of stock repurchased in FY2025 at avg price of $167/share
  • Net debt of $2.8B with net debt to adjusted EBITDA ratio of 1.8x
  • Free cash flow of $862.0M for FY2025
  • Board additions: Kevin Egan (former PwC Ireland audit leader) and Jeff Elliott (former CFO of Exact Sciences)

Financial Impact

FY2025 GAAP net income fell to $229.3M from $739.1M in FY2024; adjusted net income fell to $989.8M from $1,110.2M. Revenue restated down by $158M cumulatively over FY2023-2024. FY2026 guidance midpoint of $8,000M revenue and $10.50 adjusted EPS implies continued year-over-year decline from FY2025 levels.

revenueepsnet incomeadjusted EBITDAgoodwillbacklog

Risk Factors

  • Failure to remediate material weaknesses could lead to continued restatement risk or SEC enforcement action
  • FY2026 guidance midpoint implies revenue decline from FY2025 actuals, suggesting organic contraction
  • Backlog methodology change reduces visibility into future revenue conversion
  • Nasdaq deficiency notice from delayed 20-F filing creates listing risk
  • Goodwill and asset impairments suggest potential further write-downs in Data Solutions

Market Snapshot

Exchange
Nasdaq
Sector
Services-Commercial Physical & Biological Research
Analyst Consensus
57% bullish (23 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001628280-26-038510
Document: iconplc6kq425.htm0001628280-26-038510
Document: 0001628280-26-038510-index-headers.html0001628280-26-038510
Document: 0001628280-26-038510-index.html0001628280-26-038510
Document: 0001628280-26-038510.txt0001628280-26-038510
12 reports for ICLR
Performance horizon
60% Hit rate 3 of 5 directional calls best @ T+5▲ +3.92%Aug 6, 2026
Filters
Rows
Reports for ICLR — sortable, filterable
TypeNow
Aug 20, 2026
6w ago
6-K
NEUTRAL ★ 2/10
$174.27 $169.68▼ −2.63%▼ −2.63%$162.05 (−7.01%)
Aug 12, 2026
7w ago
Insider Cluster
NEUTRAL ★ 2/10
$167.48 $169.31▲ +1.09%▲ +2.84%$162.05 (−3.24%)
Aug 12, 2026
7w ago
Insider Cluster
NEUTRAL ★ 2/10
$167.48 $169.31▲ +1.09%▲ +2.84%$162.05 (−3.24%)
Aug 6, 2026
8w ago
6-K
BULLISH ★ 6/10
$161.17 $163.58▲ +1.50%▲ +0.90%$162.05 (+0.55%)
Jul 30, 2026
9w ago
6-K
BEARISH ★ 7/10
$165.53 $169.72▼ −2.53%▲ +1.43%$162.05 (+2.10%)
Jul 22, 2026
10w ago
6-K
NEUTRAL ★ 4/10
$167.28 $172.49▲ +3.11%▲ +0.22%$162.05 (−3.13%)
Jun 23, 2026
14w ago
6-K
BEARISH ★ 6/10
$158.17 $167.28▼ −5.76%▼ −3.83%$162.05 (−2.45%)
Jun 23, 2026
14w ago
6-K
NEUTRAL ★ 5/10
$158.17 $167.28▲ +5.76%▲ +3.83%$162.05 (+2.45%)
Jun 17, 2026
15w ago
6-K
NEUTRAL ★ 2/10
$146.00 $170.00▲ +16.44%▲ +15.91%$162.05 (+10.99%)
May 27, 2026
18w ago
6-K
BEARISH ★ 8/10
$136.80 $169.86▼ −24.17%▼ −27.31%$162.05 (−18.46%)
Showing 10 of 12

US Market Status

Market Closed — Opens Mon (38h 19m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access